Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Washington University School of Medicine
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01207921
First received: September 21, 2010
Last updated: June 30, 2014
Last verified: June 2014
  Purpose

The purpose of this study to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous transplant


Condition Intervention Phase
Hodgkin Disease
Drug: Lenalidomide
Phase 0

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after ASCT, as measured by dropout rate. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Will be described by the proportion of patients who drop out of the study for drug-related reasons at or before 12 months


Secondary Outcome Measures:
  • Overall survival, event free survival, and progression free survival. [ Time Frame: 13 months ] [ Designated as safety issue: No ]
  • Adverse event profile [ Time Frame: From start of treatment through 30 days following completion of treatment ] [ Designated as safety issue: Yes ]
    To establish the adverse event profile of long-term maintenance therapy with lenalidomide in this patient population.

  • Conversion of partial response/stable disease post-ASCT to complete response. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    To assess the conversion of partial response/stable disease post-autologous stem cell transplant to complete response.

  • Evaluate immune response [ Time Frame: Through 30 days after end of treatment ] [ Designated as safety issue: No ]
    To evaluate changes in immune cell number and function and plasma proteins before, during, and after lenalidomide therapy (correlative studies).


Estimated Enrollment: 28
Study Start Date: April 2011
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1

Lenalidomide 15 mg/day Cycle 1 (28 days).

If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.

If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day.

Drug: Lenalidomide
Other Name: Revlimid

Detailed Description:

Primary Objectives

-To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous stem cell transplant, as measured by dropout rate.

Secondary Objectives

  • To assess overall survival, event free survival, and progression free survival.
  • To establish the adverse event profile of long-term maintenance therapy with lenalidomide in this patient population.
  • To assess the conversion of partial response/stable disease post-ASCT to complete response.
  • To evaluate changes in immune cell number and function and plasma proteins before, during, and after lenalidomide therapy (correlative studies).
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must have histologically documented classical Hodgkin lymphoma that is recurrent or refractory to standard chemotherapy.
  • Core biopsies are acceptable if they contain adequate tissue for primary diagnosis and immunophenotyping. If the original diagnostic specimen is not available, relapsed or refractory specimens may be used. Bone marrow biopsies as the sole means of diagnosis are not acceptable; however, they may be used in conjunction with nodal biopsies. Fine needle aspirates (FNA) are not acceptable. Pathology reports must be submitted with the appropriate CRFs, and the actual biopsy specimens are not requested for central review. Patients with cHL have one of the following WHO subtypes:

    • Nodular sclerosis Hodgkin lymphoma
    • Lymphocyte-rich Hodgkin lymphoma
    • Mixed cellularity Hodgkin lymphoma
    • Lymphocyte-deplete Hodgkin lymphoma cHL patients without one of these subtypes designated cHL not otherwise specified are also eligible.

NOTE: Patients with nodular lymphocyte-predominant HL are not eligible.

  • Patient must have undergone autologous stem cell transplant (ASCT) between 60 and 90 days prior to study registration.
  • Patient must be ≥ 18 years old.
  • Patient must have an ECOG performance status of ≤ 2 at study entry.
  • Patient must have adequate hematologic, renal, and hepatic function as defined by:

    • Absolute neutrophil count ≥ 1000 / μL
    • Platelets ≥ 30,000 / μL
    • Serum creatinine ≤ 1.5 X institution upper limit of normal (ULN)
    • Total bilirubin ≤ 1.5 mg/dL
    • AST (SGOT) and ALT (SGPT) ≤ 3 x ULN (if not attributed to cHL)
  • Patient must be disease free of prior malignancies for ≥ 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
  • Patient must understand and voluntarily sign an informed consent form.
  • Patient must be able to adhere to the study visit schedule and other protocol requirements.
  • If a female of childbearing potential (FCBP), patient must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed
  • A FCBP is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  • A FCBP must have two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to prescribing the study drug. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative.
  • If male, patient must agree to use a latex condom during sexual contact with FCBP while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
  • Patient must be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
  • Patient must be registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of Revlimid REMS®.

Exclusion Criteria:

  • Patient who has undergone allogeneic stem cell transplantation.
  • Patient who shows evidence of progressive disease during salvage chemotherapy or following ASCT.
  • Patient has any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent him/her from signing the informed consent form.
  • Patient has any condition, including the presence of laboratory abnormalities, which places him/her at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Patient has used any other anti-cancer drug or therapy, including experimental, within 30 days of initiation of lenalidomide treatment (radiation therapy is allowed within 30 days).
  • Patient has known hypersensitivity to thalidomide.
  • Patient developed erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Patient has any prior use of lenalidomide.
  • Patient is known to be positive for HIV or infectious hepatitis, type A, B, or C.
  • Patient is pregnant or breastfeeding.
  • Patient has concurrent use of other anti-cancer agents or treatments.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01207921

Contacts
Contact: Todd Fehniger, M.D., Ph.D. 314-362-5658 tfehnige@.wustl.edu

Locations
United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Todd Fehniger, M.D.,Ph.D.         
Sub-Investigator: Nancy Bartlett, M.D., Ph.D.         
Sub-Investigator: Amanda Cashen, M.D.         
Principal Investigator: Todd Fehniger, M.D.         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Steven Devine, M.D.    614-293-9868    steve.devine@osumc.edu   
Principal Investigator: Samantha M Jaglowski, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
Celgene Corporation
Investigators
Principal Investigator: Todd Fehniger, M.D., Ph.D. Washington University School of Medicine
  More Information

Additional Information:
Publications:
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT01207921     History of Changes
Other Study ID Numbers: 201010719
Study First Received: September 21, 2010
Last Updated: June 30, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lenalidomide
Thalidomide
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on July 29, 2014